<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 67 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page66.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=67">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 67 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 67</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=67"><img src="../thumb/67.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>36 / 2020-04                                                         Central Nervous System - 1.6
   progestative-contain. hormon.contracept.at dos.of 12 mg/day & ad-  stabilisat.dos. 200 mg/day: Wk.1: 100 mg/day which is to be maint.   hepat.fail., hepatit., LFT abnormalit. tox.epiderm. necrolys., Stev.-
   dit. non-hormon.forms of contracept.recomm., withdraw grad.to stop   through wk.2 & wk.3 onwards. With curr. stabilisat.dos.300 mg/  John.syndr., erythema multiforme
   treatm., pts.at risk of fall., reduc.dos./ discont. in case of persist.ag-  day: Wk.1 150 mg/day which is to be maint.through wk.2 & wk.3 on-  Warnings and special precautions: Grad. withdr., ren.impairm.,
   gress. sympts., subst. abuse hist., concom.CYP3A induc. antiepilepts.,   wards. With curr.stabilisat.dos.400 mg/day: Wk.1 200 mg/day which   sev.imp.hepat.funct., reproduct. toxic.shown in animals, excret.in
   concom.cytochrome P450 induc./ inhibits., lact.intol., not recomm.in   is to be maint.through wk. 2 & wk.3 onwards. Addit.of enzyme in-  human breast milk, elderly with comprom.ren. funct., advis. pts.to
   mod.to sev.ren. impairm.& pts.undergo.haemodialys., not recomm.   duc. (eg.carbamazepine)when NOT tak.valproate. With curr.  immed.report any sympts.of depress.&/ suicid.ideat., excipients
   in sev. hepat.impairm., not recomm.in women of childbear. potent.  stabilisat.dos.200 mg/day: Wk.1 200 mg, in wk.2 300 mg & in wk.3   glycerol & maltitol in oral sol., incr.seiz.freq.report.
   not using contracept./pregn., unknown if excret.in breast milk, insuf-  onwards 400 mg. With curr. stabilisat.dos.150 mg/day: Wk.1 150   Drug interactions: High.anorex.risk with concom. topiramate, high.
   fic data in childr.und.12 yrs., elderly.  mg, in wk.2 225 mg & in wk.3 onwards 300 mg. With curr. stabilisat.  clear.in childr.tak. enzyme-induc.antiepilept.meds., ren.clear.of me-
   Interactions: May decr.effic.of progestative contain. oral contra-  dos.100 mg/day: Wk.1 100 mg, in wk.2 150 mg & in wk.3 onwards   tabol.poss.reduc.by meds.excret.by act.tubul. secret., no data avail.on
   cept.at dos.of 12 mg/day, plasma conc. decr.with CYP3A induc.incl.   200 mg. Addit.of other psychotrop./AED drugs with no known   influence of antacids on absorpt., no data avail.on interact.with alcoh.
   carbamazepine/ oxcarbazepine/phenytoin., clear. of oxcarbazepine   interacts.with lamotrigine (e.g. Li/bupropion): Maint.target.
   decr., AUC of concom.midazolam decr., eff.of alcoh.incr., plasma conc.  dos.achiev.in dos. escalat.(200 mg/ day) with range of 100-400 mg.  LAMICTIN, (Aspen Pharmacare) GSK [P/S]
   of perampanel decr.with strong cytochrome P450 induc. incl.rifampicin   Contraindications: Monother.in childr.und.12 yrs. not recomm.,   Lamotrigine
   & hypericum, incr.AUC & t ½ with ketoconazole.  safety in pregn.& lactat.not est., safety & effic.in childr.und.2 yrs.&   Indications: Adults & childr.over 12 yrs: Monother./ add-on
   See also MDR page 301.       pts.over 65 yrs not est., hepat./ren.impairm., lact.intol., safety & ef-  treatm.of part.epilep.with/ without second.general.ton.-clon.seiz.,
                                                              & in prim. gen. tonic-clon.seiz. Childr. 2-12 yrs: Add-on treatm. of
   GIROTEC, Aurobindo [P/S]     fic.in bipol.disord. not est.in childr.und.18 yrs.  part.epilep.with/without second gen. tonic-clonic seiz.not satisfact.
   Lamotrigine.                 Side effects: Sev.skin rash with irrevers.scarr.& assoc.death incl.  control.with other anti-epilept.medic., add-on treatm.of seiz.assoc.
   Indications: Adults & childr.over 12 yrs: Monother./add-on   tox.epiderm.necrolys & Stev.-Johns. syndr.esp.in chldr.& pts.on con-  with Lennox- Gastaut Syndr., mood episod. prevent. in bipol.disord.
   treatm.of part.epilepsy with/ without second.general.ton.clon.seiz.,   com. valproate, bld.dyscras., CNS effs., aggress., trem., paraesthes.,   predomin.by prevent. depress.episod.
   & in prim. gen. tonic-clon.seiz. Childr. 2-12 yrs: Add-on treatm. of   tiredn., vis.disturbs., nystagm., vertigo, GI disturbs., hypersens.syndr.,   (S3) TABS, [P/S] Z/2.5/280, 281, 282, 29/2.5/0472.
   part.epilep.with/without second gen. tonic-clonic seiz.not satisfact.  angioed., photosens., arthralg., pain, back pain.  805505-008: 25 mg, 60, R187,71
   control.with other anti-epilept.meds., add-on treatm.of seiz.assoc.   Warnings and special precautions: Close monit. of hepat./ren. &   805513-019: 50 mg, 60, R285,91
   with Lennox- Gastaut Syndr., mood episod. prevent. in bipol.disord.  clott.paramet., consid. withdr. if combinat.of unexplain.rash/fev./flu-  805521-003: 100 mg, 60, R447,68
   predomin.by prevent. depress.episod.  like sympts./ drowsin.or worsen.of seiz.contr.dur.1st 8 wks. of treatm.  819034-002: 200 mg, 60, R846,81
   (S3) TABS, 43/2.5/0048, 0049, 0050  exper., abrupt.withdr.may provoke rebound seiz., grad.withdr., monit.  (S3) DISPERS.TABS, [P/S] 36/2.5/0407, 29/2.5/0303, 0304, 0305,
   722725-001: 50 mg, 60, R137,25  childr.weight to maint. therap.dos., eval.all pts.prompt. if rash./ early   32/2.5/0459, 0460
   722726-001: 100 mg, 60, R230,58  manifestat.of hypersens.occur, adhere to recomm. dos.esp.if val-  704533-001: 2 mg, 30, R50,04
   722727-001: 200 mg, 60, R373,32  proate used concom., rhabdomyolys./multiorg.dysfunct.& dissemi-  813885-019: 5 mg, 100, R185,41
   Dosage: Do not exceed max.recomm.dos.esp.in combinat.with   nat. intravasc. coagulat., concom.folate antagon., investig. change   813893-003: 25 mg, 60, R187,71
   valproate. If calcul.dos.,esp.in childr. does not equate to whole tab.  in menstr.pattern in pts.tak. OC’s, close supervis.of suicid.risk pts.   891708-006: 50 mg, 60, R285,91
   admin.dos. as equal to low.no.of whole tabs.  Drug interactions: Anti-epilept.agents which induc. hepat.drug   813907-004: 100 mg, 60, R447,68
   Monotherapy: Adults & childr.over 12 yrs: Init. 25 mg once dly.  metabol.enzymes signific. enhanc. metabol., sod.valproate signific.  891716-002: 200 mg, 60, R846,81
   x2 wks., follow.by 50 mg once dly. x2 wks. Thereaft.dos.may be incr.  reduc. metabol., valproic acid plasma conc.poss reduc., being a weak   Dosage: Do not exceed max.dos esp.in combin. ther.with valproate.
   by max.50-100 mg every 1-2 wks.until optim.respons.achiev. Usual.  inhibit.of dihydrofol. reductase there is a poss.of interfer.with folate   If interact.of concom. antiepilept. with lamotrigine not known dos.
   maint.dos: 100-200 mg/day admin.once dly or in 2 div.dos.  metabol.dur.longt. ther.  escalat. as for pts.tak.valproate to be used. If calcul. dos. does not
   Add-on therapy: Adults & childr.over 12 yrs. Pts.not tak.sod.  KEPPRA, (Aspen Pharmacare) GSK [P/S]  equate to whole tab.admin. dos. as equal to low.no.of whole tabs.
   valproate: Init: 50 mg once dly x2 wks.follow.by 100 mg/day in 2   Levetiracetam  Dispers.tabs in small vol.water enough to cover tab., if pref. chew tab
   div.dos.x2 wks. thereaft. dos. should be incr.by max.100 mg every 1-2   Indications: Monother.in part.onset seiz.with/ without second.  Monotherapy: Adults & childr.over 12 yrs: Init. 25 mg once dly.
   wks.until optim.respons.achiev. Usual.maint. dos.to achieve optim.  generalisat.in pts.from 16 yrs. with new.epilep.diagn., adjunct.ther.in   x2 wks., follow.by 50 mg once dly. x2 wks. Thereaft.dos.should be
   respons: 200-400 mg/day in 2 div. dos.  partial onset seiz.with/without second.generalisat.in adults & childr.  incr.by max. 50-100 mg every 1-2 wks.until optim. respons. achiev.
   Pts.tak.sod.valproate: Init: 25 mg every altern. day x2 wks., follow   over 16 yrs., myoclon.seiz.in adults & adolesc.from 12 yrs.with juvenile   Usual.maint.dose: 100-200 mg/day admin. once a day or as 2 div.
   by 25 mg once dly.x2 wks. thereaft.dly.dos.should be incr.by max. 25-  myoclon. epilep., prim.generalis.tonic-clonic seiz. in adults & childr.  dos. 500 mg/day has been giv.
   50 mg every 1-2 wks.until optim.respons.achiev. Usual maint.dos.to   from 16 yrs with idiopath. generalis. epilep.  Add-on therapy: Adults & childr.over 12 yrs. Pts.not tak.sod.
   achieve optim.respons: 100-200 mg/ day giv.once a day/in 2 div. dos.
   Do not exceed tot.dly.dos.of 200 mg.  (S3) TABS, 36/2.5/0088, 0089, 0090  valproate: Init: 50 mg once dly x2 wks.follow.by 100 mg/day in 2
                                                              div.dos.x2 wks. thereaft.dos. should be incr.by max.100 mg every
                                700958-003: 250 mg, 60, R349,52
   Childr. 2-12 yrs: Pts.not tak.sod.valproate: Init.0.6 mg/kg bm/day in
   2 div.dos.x2 wks., follow. by 1.2 mg/kg/day x2 wks. Thereaft.the dos.  700959-009: 500 mg, 60, R301,26  1-2 wks.until optim.respons.achiev. Usual.maint. dos.to achieve op-
                                                              tim.respons: 200-400 mg/day in 2 div. dos. Pts.tak.sod.valproate:
                                703165-001: 750 mg, 60, R1 048,56
   should be incr.by a max.1.2 mg/kg every 1-2 wks.until optim. respons.
   achiev. Usual maint.dos.to achieve optim.respons: 5-15 mg/kg/day in   Dosage: Admin.dly.in 2 equal.div.dos. Insuffic. data for use in   Init: 25 mg every altern. day x2 wks., follow by 25 mg once a day x2
                                                              wks. thereaft.dos.should be incr.by max.25-50 mg every 1-2 wks.
                                childr.und.12 yrs.
   2 div.dos. Max. dly.dos.of 400 mg not to be exceed.
   Pts.tak. sod. valproate: Init: 0,15 mg/kg bm/day once dly x 2wks.   Monotherapy: Adults & adolesc.from 16 yrs: Recomm.start.dos:   until optim.respons.achiev. Usual maint. dos.to achieve optim.re-
                                                              spons: 100-200 mg/ day giv.once a day/in 2 div. dos. Do not exceed
   follow.by 0,3 mg/kg/day once a day x2 wks. Thereaft.incr.dos by   250 mg 2x dly.incr.to init. therapeut.dos.of 500 mg 2x dly.aft.2 wks.
   max.0,3 mg/kg every 1-2 wks.until optim.respons.achiev. Usual   Dos. may be furth.incr.by 250 mg 2x dly.every 2 wks. depend. on clinic.  recom. init.dos.
   maint. dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max.dly.dos.of   respons. Max.dly dos: 1 500 mg 2x dly.  Childr. 2-12 yrs: Pts.not tak.sod.valproate: 0,6 mg/kg bm/day in
   200 mg not to be exceed. If calculat. dly.dos. is 1 - 2 mg then 2 mg   Adjunct.ther: Adults (≥18 yrs) & adolesc. (12-17 yrs)   2 div.dos.x2 wks.,follow.by 1,2 mg/kg/day x2 wks. Thereaft.the dos.
   may be tak. on altern. days for 1st 2 wks. If calculat.dly.dos &lt; 1 mg   weigh.50 kg or more,when indic.  should be incr.by a max.1,2 mg/kg every 1-2 wks.until optim. respons.
                                                   st
   then GIROTEC should not be admin. Pts.aged 2-6 yrs. may require   Init.therapeut.dos: 500 mg 2xdly start.on 1  day of ther. Depend.on   achiev. Usual maint.dos.to achieve optim. respons: 5-15 mg/kg/day in
   maint.dos. at high.end of scale.  respons.& toler.dly.dos.may be incr. up to 1 500 mg 2xdly. Dos.chang.  2 div.dos. Max.dly. dos. of 400 mg not to be exceed.
   Lennox-Gastaut Syndr: Dos.guidelines as above for adults &   made in incrm./ decrm.of 500 mg 2xdly.every 2-4 wks.  Pts.tak.sod.valproate: Init: 0,15 mg/kg bm/day once dly x 2wks.
   childr.aged 2-12 yrs.        Adolesc.(12-17 yrs)weigh.less than 50 kg, when indic: Init.thera-  follow.by 0,3 mg/kg/day once a day x2 wks. Thereaft.incr.dos by
   Bipolar.disord: Adults over 18 yrs: Do not exceed init.dos.& sub-  peut.dos: 10 mg/kg 2x dly start. on first day of treatm. Dos.may be   max.0,3 mg/kg every 1-2 wks.until optim.respons.achiev. Usual maint.
   seq.escalat.dos. Follow. transit. regim.of dos.escalat.to maint.dos.  incr.up to 30 mg/kg 2x dly.depend.on respons.& toler. Dos. chang.not   dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max. dly.dos.of 200 mg not
   over 6 wks. to prev.recurr.of depress.episod. Other psychotrop. and/  to exceed incr./decr.of 10 mg/kg 2x dly. every 2 wks. Use low.eff.dos.  to be exceed. If calcul. dly.dos.is 1 -2 mg, 2 mg tab may be taken on
   or anti-epilept.drugs can then be withdr. if indicat. Consid.adjunct.  Childr.50 kg or great: Adult dos.  altern. days for the first 2 wks. Do not admin.if calcul. dos.is less than
   ther.for prev.of man. episod.as effic.not conclus.est. If lamotrigine is   Elderly (≥ 65 yrs.): Adjustm.of dos.recommend. in elderly pts. with   1 mg. Pts.aged 2-6 yrs.may require maint.dos.at high.end of scale.
   to be terminat.no stepwise dos.reduct.is necess.  comprom.ren.funct. Ref.to prof. info.  Lennox-Gastaut Syndr: Dos.guidelines as above for adults &
   Recomm.dos.escalat.in Bipol.disord: Adjunct. ther.with en-  (S3) ORAL SOL, A40/2.5/0587  childr.aged 2-12 yrs.
   zyme inhibit. (eg.valproate): Init.25 mg every alt.day x2 wks. follow.  Indications: Adjunct.ther.in part.onset seiz.with / without second.  Bipolar.disord: Adults over 18 yrs: Do not exceed init.dos.& sub-
   by 25 mg once dly. x2 wks. Incr.dos.to 50 mg once dly/in 2 div. dos.in   generalisat.in adults & childr. from 4 yrs with epilep.  seq.escalat.dos. Follow. transit. regim.of dos.escalat.to maint.dos.
   wk.5. Usual target dos.is 100 mg/day admin once dly/in 2 div.dos.but   714166-001: 100 mg/ml, 300 ml, R442,84  over 6 wks. to prev.recurr.of depress.episod. Other psychotrop. and/
   maybe incr.to max. 200 mg/day depend.on clinic.respons. Adjunct.  Dosage: May be dilut.in glass of water. Dly.dos. admin.in 2 equal.  or anti-epilept.drugs can then be withdr.if indicat. Consid.adjunct.ther.
   ther.with enzyme induc. (eg.carbamazepine) in pts.NOT tak.  div.dos.  for prev.of man. episod.as effic.not conclus.est. If lamotrigine is to be
   valproate: Init.50 mg once dly x 2 wks.follow.by 100 mg/day in 2   Adults (&gt;18 yrs) & adolesc.(12-17 yrs): As adjunct. ther.init.ther-  terminat.no stepwise dos.reduct.is necess.
   div.dos.x2 wks. Incr.to 200 mg/day admin.in 2 div. dos.in wk.5.& may   apeut.dos.is 500 mg 2x dly. start. on first day. Dly.dos.may be incr.  Recomm.dos.escalat.in bipol.disord: Adjunct. ther.with en-
   be incr.in wk.6 to 300 mg/day. Usual target dos.is 400 mg/day in 2   up to 1 500 mg 2x dly.depend.on clinic.respons.& toler. Dos. chang.  zyme inhibit. (eg.valproate): Init.25 mg every alt.day x2 wks.follow.
   div. dos.admin.from wk.7. Adjunct.ther.to drugs with no known   can be made in 500 mg 2x dly increm./ decrem.every 2-4 wks. Max.  by 25 mg once dly. x2 wks. Incr.dos.to 50 mg once dly/in 2 div.dos.in
   clinic.interacts.(eg. Li/bupropion) OR as monother: Init.25 mg   dly.dos: 3 000 mg  wk.5. Usual target dos.is 100 mg/day admin once dly/in 2 div.dos.but
                                                       st
   once dly. x2 wks.follow. by 50 mg once dly./in 2 div. dos. x2 wks.incr.  Childr.4-11 yrs: Init.dos: 10 mg/kg 2xdly.start.on 1  day of ther.   maybe incr.to max.200 mg/day depend.on clinic.respons. Adjunct.
   to 100 mg/day in wk.5. Usual target dos.is 200 mg once dly/in 2 div.   Dly.dos.may be incr.up to 30 mg/kg 2xdly.depend.on clinic.respons   ther.with enzyme induc. (eg.carbamazepine) in pts.NOT tak.
   Dos.range of 100-400 mg used in clinic. trails.  & toler. Dos.incrm./ decrm.of 10 mg /kg 2xdly.every 2wks. Dos.in   valproate: Init.50 mg once dly x 2 wks.follow.by 100 mg/day in 2
   Maint.stabilisat.tot.dly.dos.in Bipol.disord. follow.concom.  childr. 50 kg or great.same as adults. Childr.20 kg or less pref.start   div.dos.x2 wks. Incr.to 200 mg/ day admin.in 2 div.dos.in wk.5.& may
   psychotrop./anti-epilept.drug withdr: Follow.withdr.of ad-  treatm.with Oral Sol.  be incr.in wk.6 to 300 mg/day. Usual target dos.is 400 mg/day in 2
   junct.enzyme inhibit. (e.g. valproate): Double stabilisat.dos.not   Elderly (≥ 65 yrs.): Adjustm.of dos.recommend. in elderly pts.with   div.dos.admin.from wk.7. Adjunct.ther.to drugs with no known
   exceed.100 mg/wk.in wk.1 (i.e.100 mg/day will be incr.to 200 mg/  comprom.ren.funct. Ref.to prod.info.  clinic.interacts.(eg. Li/bupropion) OR as monother: Init.25 mg
   day in wk.1). Maint.200 mg/day admin. in 2 div.dos.in wk.2 & 3 on-  Contraindications: Pyrrolidone derivat. hypersens., pregn., safety   once dly. x2 wks.follow. by 50 mg once dly./in 2 div. dos. x2 wks.incr.
   wards. Follow.withdr.of adjunct.enzyme induc. (eg.carbamaz-  in lactat.not est., Oral sol. also heredit.problem of fruct.intol., insuf-  to 100 mg/day in wk.5. Usual target dos.is 200 mg once dly/in 2 div.
   epine) depend.on origin.dos: Reduc. dos.grad.over 3 wks.as en-  fic. data in childr.und.4  yrs.  Dos.range of 100-400 mg used in clinic.trails.
   zyme induc. withdr. If in wk.1 400 mg then wk.2 300 mg & wk.3 200   Side effects: Somnol., asthen., dizzin., fatig., amnes., atax., convuls.,   Maint.stabilisat.tot.dly.dos.in bipol.disord. follow.concom.
   mg. If in wk.1 300 mg then wk.2: 225 mg & wk.3: 150 mg. If in wk.1   headache, hyperkines., tremor, bal.disord., attent.disturb., memory   psychotrop./anti-epilept. drug withdr: Follow.withdr.of ad-
   200 mg then wk.2: 150 mg & wk.3: 100 mg. Follow.withdr.of other   impairm., agitiat., depress., emot.lability, hostility, aggress., insomn.,   junct. enzyme inhibit. (e.g. valproate): Double stabilisat.dos.
   psychotrop. / AED drugs with no known interacts.with lamo-  nervousn., irritibil., person. disords., abnorm.think., GI disturbs., ano-  not exceed.100 mg/wk.in wk.1 (i.e.100 mg/day will be incr.to 200
   trigine (e.g. Li/bupropion): Maint.target.dos.achiev.in dos.escalat.  rex., weight chang., vertigo, diplopia, blurr. vis., myalg., accid.injury,   mg/day in wk.1). Maint.200 mg/day admin. in 2 div.dos.in wk.2 &
   throughout withdr.of other med.  infect., nasopharyngit., incr. cough, skin rash, eczema, prurit., psych.   3 onwards. Follow. withdr.of adjunct.enzyme induc. (eg.car-
   Lamotrigine dly.dos.adjustm.in bipol.disord. follow.addit.of   disords. incl. psychot.disord./suicide/suic. attempt/ suic.ideat., alo-  bamazepine) depend.on origin.dos: Reduc. dos.grad.over 3 wks.
   other meds: Addit.of enzyme inhibit.(eg.valproate). With curr.  pec., bld.dyscras.incl. bone marr.suppress., paraesthes., pancreatit.,   as enzyme induc. withdr. If in wk.1 400 mg then wk.2 300 mg & wk.3</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page66.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page62.html">62</a>&nbsp;&nbsp;&nbsp;<a href="page63.html">63</a>&nbsp;&nbsp;&nbsp;<a href="page64.html">64</a>&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>
             </td>
             <td width="35%"><a href="page68.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page68.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
